SAN DIEGO, Dec. 19 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. announced today that Steve Worland, Ph.D. will assume additional key responsibilities, including strategic planning and corporate development while continuing to lead Anadys R&D efforts. His new title will be Executive Vice President, Pharmaceuticals. Additionally, Mary Yaroshevsky- Glanville has been promoted to Vice President, Human Capital.
“I wish to congratulate both Steve and Mary who have been valuable members of the executive management team of Anadys for more than four years,” said Kleanthis G. Xanthopoulos, Ph.D., Anadys’ President and CEO. “I am pleased to see that Steve’s increasing responsibilities will link Anadys’ scientific and commercial efforts. These are critical tasks as we seek to enhance our product pipeline in the years ahead.”
“I am also delighted with Mary’s development and advancement at Anadys,” said Dr. Xanthopoulos. “She has been instrumental in establishing, promoting and embodying Anadys’ vision, core values, and beliefs.”
Dr. Worland and Ms. Yaroshevsky-Glanville, who are members of Anadys’ Strategic Committee, will continue to report to Dr. Xanthopoulos.
Dr. Worland joined Anadys as Chief Scientific Officer in 2001 and was promoted to Executive Vice President, Research and Development in October 2004. He received a B.S. degree in Biological Chemistry from the University of Michigan and a Ph.D. in Chemistry from the University of California, Berkeley. He was a National Institutes of Health Postdoctoral Fellow in Molecular Biology at Harvard University from 1985 to 1988.
Ms. Yaroshevsky-Glanville joined Anadys in April 2001 as Director of Human Capital and was promoted to Senior Director, Human Capital in August 2002. She has a Human Resources Management Certificate from the British Columbia Institute of Technology and a Certified Human Resources Professional designation from the Human Resources Management Association. Ms. Yaroshevsky- Glanville received a B.S. degree in Computer Information System Management from DeVry Institute of Technology, Oakbrook, Illinois.
About Anadys
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule medicines for the treatment of hepatitis, other serious infections, and cancer. The Company has core expertise in Toll-Like Receptor-based small molecule therapeutics and structure-based drug design coupled with medicinal chemistry. Anadys’ clinical development programs include ANA975 for the treatment of HCV and HBV, and ANA380 for the treatment of HBV. In addition, Anadys’ therapeutic platform is designed to advance a strong and continual pipeline of drug candidates into the clinic.
Safe Harbor Statement
Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys’ actual results to be materially different from historical results or from any results expressed or implied by such forward- looking statements. In particular, the results of initial clinical trials may not be predictive of future results, and Anadys cannot provide any assurances that any of its product candidates will have favorable results in future clinical trials or receive regulatory approval. In addition, Anadys’ results may be affected by risks related to the implementation of its collaboration with Novartis, competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to successfully develop and market products, the level of effort that its collaborative partners devote to development and commercialization of its product candidates, difficulties or delays in its clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments involving future products and its ability to obtain additional funding to support its operations. These and other factors that may cause actual results to differ are more fully discussed in the “Risk Factors” section of Anadys’ Form 10-Q for the quarter ended September 30, 2005. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
Anadys Pharmaceuticals, Inc.
CONTACT: Vince Reardon, Sr. Director, Investor Relations & CorporateCommunications, of Anadys Pharmaceuticals, Inc., +1-858-530-3653,vreardon@anadyspharma.com
Web site: http://www.anadyspharma.com//
